Human Phospho-Axl (Y779) Antibody

Detection of Human Axl by Western Blot

Clinical drug responses were evaluated in the patient-derived primary culture GBM cells. (a) Most of the primary culture cancer cells were CD133 (green) and SOX2 (red), highly expressed using flow cytometry analysis and immunofluorescence assay. Hoechst33342-labeled nuclei. Bar = 50 μm. MFI: mean fluorescent intensity. (b) Flow cytometry analysis and immunofluorescence assay in GBM primary cultured spheroid cells to detect the high expression of CD133 (green) and SOX2 (red) cultured with serum-free medium. Hoechst33342-labeled nuclei. Bar = 50 μm. MFI: mean fluorescent intensity. (c) Primary culture cancer cells, treated with (Z)-BP and temozolomide (active form MTIC was used), presented relatively low IC50, compared to BCNU. Additionally, dosing (Z)-BP in IC30 concentration could reduce the required amount of TMZ for determining the synergistic effect on eliminating primary culture gliomas. (d) Using (Z)-BP (200 or 400 μM) to expose the primary culture cells could reduce the level of MGMT, in comparison to vehicle control and BCNU (800 μM). Further, receptor tyrosine kinases including EGFR, phosphorylated EGFR, and Axl were also downregulated. Upstream mTOR activity was inactivated (p-mTOR) by (Z)-BP, and this could mutually affect Axl and EGFR signaling and then decrease the protein level of PD-L1. beta-Actin was used as an internal control. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35646111), licensed under a CC-BY license. Not internally tested by R&D Systems.